Fig. 2: Clinical values of lnc-OPHN1-5 (lnc-5) in prostate cancer (PCa). | Cell Death & Disease

Fig. 2: Clinical values of lnc-OPHN1-5 (lnc-5) in prostate cancer (PCa).

From: Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression

Fig. 2

A Sorting the PCa samples by lnc-5 expression determined by reverse transcription-polymerase chain reaction (RT-PCR) assay. B Displaying the recurrent status of PCa patients in high- and low-lnc-5 expression subgroups. C Kaplan–Meier plot and log-rank analysis suggested that the patients with lower expression of lnc-5 had worse recurrence-free survival outcomes than those with higher lnc-5 expression. D The relative lnc-5 expression in patient-derived Xenograft (PDX) models after long-time Enzalutamide (Enz)-treatment compared with controls determined by RT-PCR assay. E The relative lnc-5 expression in C4-2R & C4-2BR cells compared with parental C4-2 & C4-2B cells determined by RT-PCR assay. *P < 0.05; **P < 0.01.

Back to article page